Compare SOTK & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOTK | GANX |
|---|---|---|
| Founded | 1975 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 78.2M |
| IPO Year | 1995 | 2021 |
| Metric | SOTK | GANX |
|---|---|---|
| Price | $5.39 | $1.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 40.6K | ★ 697.2K |
| Earning Date | 05-27-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | 31.46 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $20,909,315.00 | $55,180.00 |
| Revenue This Year | $4.02 | N/A |
| Revenue Next Year | $10.95 | N/A |
| P/E Ratio | $47.91 | ★ N/A |
| Revenue Growth | ★ 1.97 | N/A |
| 52 Week Low | $3.23 | $1.41 |
| 52 Week High | $5.74 | $4.34 |
| Indicator | SOTK | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 56.19 | 43.47 |
| Support Level | $3.79 | $1.65 |
| Resistance Level | $5.72 | $2.12 |
| Average True Range (ATR) | 0.39 | 0.13 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 65.29 | 26.53 |
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.